PR Newswire

Indeks Tulisan

Press Release
Selasa, 8 Sept

Subsidiary of Greenland Technologies Receives Government Incentive Program Approvals for Its Heavy Electric Industrial Vehicles

HANGZHOU, China, Sept. 8, 2026 /PRNewswire/ -- HEVI Corp., a wholly owned subsidiary of Greenland Technologies Holding Corporation (NASDAQ: GTEC) ("Greenland" or the "Company"), a developer and manufacturer of transmission and drivetrain systems for material handling machinery and electric industria
Press Release
Selasa, 8 Sept

Metabolon Verus™ Metabolomics Profiling Kit Now Available to Order

A successful multi-site ring trial and early access program demonstrate the reproducibility, scalability, and biological insight of the Metabolon Verus™ Metabolomics Profiling Kit across laboratories worldwide MORRISVILLE, N.C., Sept. 8, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in pro
Press Release
Selasa, 8 Sept

One Year In, Drunk Angel Defines Its Distinctive Approach to Crystal Jewelry

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- One year after establishing its online presence, Drunk Angel is marking its first anniversary by defining the approach that has taken shape across its collections: pairing natural gemstones and their traditional meanings with contemporary jewelry design. Found
Press Release
Selasa, 8 Sept

Reimagining finance: DIFC to convene global leaders across banking, private markets, asset management, FinTech, public policy and sustainability at Dubai Future Finance Week

DUBAI, UAE, Sept. 8, 2026 /PRNewswire/ -- Dubai International Financial Centre (DIFC), the leading global financial centre in the Middle East, Africa and South Asia region, has confirmed the programme for the inaugural edition of Dubai Future Finance Week, held from 2 to 6 November 2026, examining f
Press Release
Selasa, 8 Sept

Aurzen Shines at IFA 2026, Garnering 11 Honors Across Its Projector Lineup

IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- Aurzen made a strong impression at IFA 2026, with its latest projectors earning recognition from media and the show's own innovation award. Aurzen Shines at IFA 2026, Garnering 11 Honors Across Its Projector Lineup The Aurzen ZIP Pro appeared in best-of-
Press Release
Selasa, 8 Sept

ClubMed Lifestyle Group Advances Global Expansion Through Industry Collaboration and AI Application

HONG KONG, Sept. 8, 2026 /PRNewswire/ -- ClubMed Lifestyle Group, a subsidiary of Fosun International Limited (656), has joined the World Travel & Tourism Council (WTTC) as a Global Member. The membership was announced by WTTC on August 28. ClubMed Lifestyle Group operates premium all-inclusive reso
Rilis Pers
Selasa, 8 Sept

Kolmar Korea Hadirkan Tabir Surya dengan Sensasi Sejuk pada Kulit di Tengah Gelombang Panas Ekstrem yang Semakin Intens di Seluruh Dunia

Kolmar Korea memperkuat inovasi produk perawatan kulit dari sinar matahari khas Korea dengan bahan penyejuk nonmentol, teknologi water-drop, dan Jelly Sun Stick yang memiliki kandungan air tinggi Formula penyejuk terbaru mampu menurunkan suhu kulit sekitar 4–6°C dan memberikan perlindungan UV yang k
Press Release
Selasa, 8 Sept

As Global Heatwaves Intensify, Kolmar Korea Brings Cooling Innovation to Sunscreen

Kolmar Korea advances K-sun care with non-menthol cooling ingredients, water-drop technology, and a high-moisture Jelly Sun Stick New cooling formulations lower skin temperature by approximately 4–6°C while delivering robust UV protection SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Kolmar Kore
Press Release
Selasa, 8 Sept

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("F
Press Release
Selasa, 8 Sept

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. HBM9378/WIN378 produced signific